{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:22:51Z","timestamp":1790875371162,"version":"4.1.0"},"reference-count":114,"publisher":"China Science Publishing & Media Ltd.","issue":"3","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2014,3,1]]},"DOI":"10.1093\/abbs\/gmt150","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T01:54:22Z","timestamp":1390355662000},"page":"190-198","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":44,"title":["Role of erbB3 receptors in cancer therapeutic resistance"],"prefix":"10.3724","volume":"46","author":[{"given":"Youngseok","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingcao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeree","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"null","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","volume":"9","author":"Baselga J","year":"2009","unstructured":"Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer, 2009, 9: 463-475.","journal-title":"Nat Rev Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","volume":"21","author":"Hynes NE","year":"2009","unstructured":"Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol, 2009, 21: 177-184.","journal-title":"Curr Opin Cell Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"Hynes NE","year":"2005","unstructured":"Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 2005, 5: 341-354.","journal-title":"Nat Rev Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J","volume":"87","author":"DeFazio A","year":"2000","unstructured":"DeFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer, 2000, 87: 487-498.","journal-title":"Int J Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","volume":"19","author":"Olayioye MA","year":"2000","unstructured":"Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J, 2000, 19:","journal-title":"EMBO J"},{"key":"null","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0092-8674(02)00963-7","volume":"110","author":"Ogiso H","year":"2002","unstructured":"Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 2002, 110: 775-787.","journal-title":"Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(03)00047-9","volume":"11","author":"Ferguson KM","year":"2003","unstructured":"Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell, 2003, 11: 507-517.","journal-title":"Mol Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1097-2765(03)00350-2","volume":"12","author":"Burgess AW","year":"2003","unstructured":"Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA. An open-and-shut case? Recent insights into the activation of EGF\/ErbB receptors. Mol Cell, 2003, 12: 541-552.","journal-title":"Mol Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1126\/science.1074611","volume":"297","author":"Cho HS","year":"2002","unstructured":"Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science, 2002, 297: 1330-1333.","journal-title":"Science"},{"key":"null","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","volume":"16","author":"Graus-Porta D","year":"1997","unstructured":"Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J, 1997, 16: 1647-1655.","journal-title":"EMBO J"},{"key":"null","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","volume":"21","author":"Mendelsohn J","year":"2003","unstructured":"Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 2003, 21: 2787-2799.","journal-title":"J Clin Oncol"},{"key":"null","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.tcb.2006.07.003","volume":"16","author":"Boudeau J","year":"2006","unstructured":"Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. Trends Cell Biol, 2006, 16: 443-452.","journal-title":"Trends Cell Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0014-4827(02)00101-5","volume":"284","author":"Citri A","year":"2003","unstructured":"Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res, 2003, 284: 54-65.","journal-title":"Exp Cell Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1073\/pnas.1002753107","volume":"107","author":"Shi F","year":"2010","unstructured":"Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3\/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA, 2010, 107: 7692-7697.","journal-title":"Proc Natl Acad Sci USA"},{"key":"null","doi-asserted-by":"crossref","first-page":"2005.0008","DOI":"10.1038\/msb4100012","volume":"1","author":"Schulze WX","year":"2005","unstructured":"Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol, 2005, 1:","journal-title":"Mol Syst Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.semcdb.2010.08.007","volume":"21","author":"Amin DN","year":"2010","unstructured":"Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol, 2010, 21: 944-950.","journal-title":"Semin Cell Dev Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","volume":"100","author":"Holbro T","year":"2003","unstructured":"Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA, 2003, 100: 8933-8938.","journal-title":"Proc Natl Acad Sci USA"},{"key":"null","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","volume":"68","author":"Lee-Hoeflich ST","year":"2008","unstructured":"Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res, 2008, 68: 5878-5887.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/187152211795495643","volume":"11","author":"Jathal MK","year":"2011","unstructured":"Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the new RTK(id) on the prostate cancer block. Immunol Endocr Metab Agents Med Chem, 2011, 11: 131-149.","journal-title":"Immunol Endocr Metab Agents Med Chem"},{"key":"null","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2010.02.023","volume":"17","author":"Mills GB","year":"2010","unstructured":"Mills GB, Yarden Y. The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. Cancer Cell, 2010, 17: 217-218.","journal-title":"Cancer Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ccr.2009.12.047","volume":"17","author":"Sheng Q","year":"2010","unstructured":"Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z. An activated ErbB3\/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell, 2010, 17: 298-310.","journal-title":"Cancer Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"Engelman JA","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316: 1039-1043.","journal-title":"Science"},{"key":"null","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1158\/0008-5472.CAN-12-1611","volume":"73","author":"Huang S","year":"2013","unstructured":"Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res, 2013, 73: 824-833.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/jcp.24037","volume":"227","author":"Aurisicchio L","year":"2012","unstructured":"Aurisicchio L, Marra E, Luberto L, Carlomosti F, De Vitis C, Noto A, Gunes Z. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors. J Cell Physiol, 2012, 227: 3381-3388.","journal-title":"J Cell Physiol"},{"key":"null","doi-asserted-by":"crossref","first-page":"744","DOI":"10.18632\/oncotarget.550","volume":"3","author":"Aurisicchio L","year":"2012","unstructured":"Aurisicchio L, Marra E, Roscilli G, Mancini R, Ciliberto G. The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget, 2012, 3: 744-758.","journal-title":"Oncotarget"},{"key":"null","first-page":"817304","volume":"2012","author":"Jiang N","year":"2012","unstructured":"Jiang N, Saba NF, Chen ZG. Advances in targeting HER3 as an anticancer therapy. Chemother Res Pract, 2012, 2012:","journal-title":"Chemother Res Pract"},{"key":"null","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.febslet.2004.06.014","volume":"569","author":"Berger MB","year":"2004","unstructured":"Berger MB, Mendrola JM, Lemmon MA. ErbB3\/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett, 2004, 569: 332-336.","journal-title":"FEBS Lett"},{"key":"null","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1073\/pnas.87.13.4905","volume":"87","author":"Plowman GD","year":"1990","unstructured":"Plowman GD, Whitney GS, Neubauer MG, Green JM, McDonald VL, Todaro GJ, Shoyab M. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci USA, 1990, 87: 4905-4909.","journal-title":"Proc Natl Acad Sci USA"},{"key":"null","first-page":"1813","volume":"10","author":"Alimandi M","year":"1995","unstructured":"Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene, 1995, 10:","journal-title":"Oncogene"},{"key":"null","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.bjc.6603910","volume":"97","author":"Hsieh A","year":"2007","unstructured":"Hsieh A, Moasser M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer, 2007, 97: 453-457.","journal-title":"Br J Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1002\/j.1460-2075.1995.tb00101.x","volume":"14","author":"Wallasch C","year":"1995","unstructured":"Wallasch C, Weiss F, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2\/neu oncogenic signaling by heterodimerization with HER3. EMBO J, 1995, 14: 4267-4275.","journal-title":"EMBO J"},{"key":"null","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/onc.2010.257","volume":"29","author":"Chakrabarty A","year":"2010","unstructured":"Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga C. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene, 2010, 29: 5193-5203.","journal-title":"Oncogene"},{"key":"null","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/ijc.22423","volume":"120","author":"Liu B","year":"2007","unstructured":"Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer, 2007, 120: 1874-1882.","journal-title":"Int J Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1158\/1541-7786.MCR-08-0509","volume":"7","author":"Liu B","year":"2009","unstructured":"Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling. Mol Cancer Res, 2009, 7: 1882-1892.","journal-title":"Mol Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/1078-0432.CCR-11-1186","volume":"18","author":"Beji A","year":"2012","unstructured":"Beji A, Horst D, Engel J, Kirchner T, Ullrich A. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res, 2012, 18: 956-968.","journal-title":"Clin Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0046-8177(98)90444-0","volume":"29","author":"Maurer CA","year":"1998","unstructured":"Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, Korc M. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol, 1998, 29: 771-777.","journal-title":"Hum Pathol"},{"key":"null","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccr.2013.04.012","volume":"23","author":"Jaiswal BS","year":"2013","unstructured":"Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S. Oncogenic ERBB3 mutations in human cancers. Cancer Cell, 2013, 23: 603-617.","journal-title":"Cancer Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"974","DOI":"10.5858\/2004-128-974-EGFRSI","volume":"128","author":"Grupka NL","year":"2004","unstructured":"Grupka NL, Lear-Kaul KC, Kleinschmidt-DeMasters BK, Singh M. Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2\/neu status. Arch Pathol Lab Med, 2004, 128: 974-979.","journal-title":"Arch Pathol Lab Med"},{"key":"null","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.11273","volume":"106","author":"Bieche I","year":"2003","unstructured":"Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer, 2003, 106: 758-765.","journal-title":"Int J Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J","volume":"87","author":"deFazio A","year":"2000","unstructured":"deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer, 2000, 87: 487-498.","journal-title":"Int J Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"R708","DOI":"10.1186\/bcr1281","volume":"7","author":"Kim A","year":"2005","unstructured":"Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res, 2005, 7: R708-R718.","journal-title":"Breast Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/emboj\/18.8.2149","volume":"18","author":"Siegel PM","year":"1999","unstructured":"Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu\/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J, 1999, 18: 2149-2164.","journal-title":"EMBO J"},{"key":"null","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4161\/cbt.10.6.12532","volume":"10","author":"Liles JS","year":"2010","unstructured":"Liles JS, Arnoletti JP, Tzeng CW, Howard JH, Kossenkov AV, Kulesza P, Heslin MJ. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol Ther, 2010, 10: 555-563.","journal-title":"Cancer Biol Ther"},{"key":"null","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-08-0186","volume":"14","author":"Reschke M","year":"2008","unstructured":"Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res, 2008, 14: 5188-5197.","journal-title":"Clin Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1158\/1078-0432.CCR-04-1633","volume":"11","author":"Barnes NL","year":"2005","unstructured":"Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res, 2005, 11: 2163-2168.","journal-title":"Clin Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/bjc.1998.689","volume":"78","author":"Naidu R","year":"1998","unstructured":"Naidu R, Yadav M, Nair S, Kutty M. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer, 1998, 78: 1385-1390.","journal-title":"Br J Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2559.1994.tb01324.x","volume":"25","author":"Quinn C","year":"1994","unstructured":"Quinn C, Ostrowski J, Lane S, Loney D, Teasdale J, Benson E. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology, 1994, 25: 247-252.","journal-title":"Histopathology"},{"key":"null","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/bjc.1992.420","volume":"66","author":"Lemoine N","year":"1992","unstructured":"Lemoine N, Barnes D, Hollywood D, Hughes C, Smith P, Dublin E, Prigent S. Expression of the ERBB3 gene product in breast cancer. Br J Cancer, 1992, 66: 1116-1121.","journal-title":"Br J Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/bjc.1996.342","volume":"74","author":"Travis A","year":"1996","unstructured":"Travis A, Pinder S, Robertson J, Bell J, Wencyk P, Gullick W, Nicholson R. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer, 1996, 74: 229-233.","journal-title":"Br J Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0959-8049(05)80010-3","volume":"30","author":"Gasparini G","year":"1994","unstructured":"Gasparini G, Pozza F, Bevilacqua P, Gullick W, Lemoine N, Maluta S, Palma P. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma\u2014an immunocytochemical study. Eur J Cancer, 1994, 30: 16-22.","journal-title":"Eur J Cancer"},{"key":"null","first-page":"4217","volume":"6","author":"Pawlowski V","year":"2000","unstructured":"Pawlowski V, R\u00e9villion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res, 2000, 6: 4217-4225.","journal-title":"Clin Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/path.1370","volume":"200","author":"Witton CJ","year":"2003","unstructured":"Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett J. Expression of the HER1\u20134 family of receptor tyrosine kinases in breast cancer. J Pathol, 2003, 200: 290-297.","journal-title":"J Pathol"},{"key":"null","doi-asserted-by":"publisher","first-page":"R2","DOI":"10.1186\/bcr1843","volume":"10","author":"Sassen A","year":"2008","unstructured":"Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G. Cytogenetic analysis of HER1\/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res, 2008, 10:","journal-title":"Breast Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.11273","volume":"106","author":"Bi\u00e8che I","year":"2003","unstructured":"Bi\u00e8che I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer, 2003, 106: 758-765.","journal-title":"Int J Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1309\/GA5VRFQFY5D0MVKD","volume":"128","author":"Lee Y","year":"2007","unstructured":"Lee Y, Cho S, Seo JH, Shin BK, Kim HK, Kim I, Kim A. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast. Am J Clin Pathol, 2007, 128: 1041-1049.","journal-title":"Am J Clin Pathol"},{"key":"null","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/sj.bjc.6604769","volume":"99","author":"Koutras A","year":"2008","unstructured":"Koutras A, Kalogeras K, Dimopoulos M, Wirtz R, Dafni U, Briasoulis E, Pectasides D. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer, 2008, 99: 1775-1785.","journal-title":"Br J Cancer"},{"key":"null","first-page":"4467","volume":"61","author":"Lee H","year":"2001","unstructured":"Lee H, Akita RW, Sliwkowski MX, Maihle NJ. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res, 2001, 61: 4467-4473.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1083\/jcb.200109033","volume":"157","author":"Offterdinger M","year":"2002","unstructured":"Offterdinger M, Sch\u00f6fer C, Weipoltshammer K, Grunt TW. c-erbB-3 a nuclear protein in mammary epithelial cells. J Cell Biol, 2002, 157: 929-940.","journal-title":"J Cell Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/SLA.0b013e3181dbb77e","volume":"251","author":"Chiu CG","year":"2010","unstructured":"Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG, Wiseman SM. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg, 2010, 251: 1107-1116.","journal-title":"Ann Surg"},{"key":"null","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/djs501","volume":"105","author":"Ocana A","year":"2013","unstructured":"Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst, 2013, 105: 266-273.","journal-title":"J Natl Cancer Inst"},{"key":"null","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1158\/1078-0432.CCR-12-0392","volume":"18","author":"Tanizaki J","year":"2012","unstructured":"Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res, 2012, 18: 6219-6226.","journal-title":"Clin Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-005-9023-9","volume":"95","author":"Contessa JN","year":"2006","unstructured":"Contessa JN, Abell A, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK. Compensatory ErbB3\/c-Src signaling enhances carcinoma cell survival to ionizing radiation. Breast Cancer Res Treat, 2006, 95: 17-27.","journal-title":"Breast Cancer Res Treat"},{"key":"null","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ccr.2011.10.006","volume":"20","author":"Vlacich G","year":"2011","unstructured":"Vlacich G, Coffey RJ. Resistance to EGFR-targeted therapy: a family affair. Cancer Cell, 2011, 20: 423-425.","journal-title":"Cancer Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"ra68","DOI":"10.1126\/scisignal.2004008","volume":"6","author":"Kirouac DC","year":"2013","unstructured":"Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2\/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal, 2013, 6:","journal-title":"Sci Signal"},{"key":"null","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-09-1218","volume":"16","author":"Campbell MR","year":"2010","unstructured":"Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res, 2010, 16: 1373-1383.","journal-title":"Clin Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1741-7007-2-24","volume":"2","author":"Mattoon D","year":"2004","unstructured":"Mattoon D, Lamothe B, Lax I, Schlessinger J. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K\/Akt cell survival pathway. BMC Biol, 2004, 2:","journal-title":"BMC Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1074\/jbc.M410436200","volume":"280","author":"Suenaga A","year":"2005","unstructured":"Suenaga A, Takada N, Hatakeyama M, Ichikawa M, Yu X, Tomii K, Okimoto N. Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides. J Biol Chem, 2005, 280: 1321-1326.","journal-title":"J Biol Chem"},{"key":"null","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1074\/jbc.M109391200","volume":"277","author":"Hemi R","year":"2002","unstructured":"Hemi R, Paz K, Wertheim N, Karasik A, Zick Y, Kanety H. Transactivation of ErbB2 and ErbB3 by tumor necrosis factor-\u03b1 and anisomycin leads to impaired insulin signaling through serine\/threonine phosphorylation of IRS proteins. J Biol Chem, 2002, 277: 8961-8969.","journal-title":"J Biol Chem"},{"key":"null","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"Vivanco I","year":"2002","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol-3-kinase\u2014AKT pathway in human cancer. Nat Rev Cancer, 2002, 2: 489-501.","journal-title":"Nat Rev Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1038\/sj.onc.1206394","volume":"22","author":"Knuefermann C","year":"2003","unstructured":"Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M. HER2\/PI-3K\/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene, 2003, 22: 3205-3212.","journal-title":"Oncogene"},{"key":"null","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(24)01479-0","volume":"53","author":"Clarke R","year":"2001","unstructured":"Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev, 2001, 53: 25-72.","journal-title":"Pharmacol Rev"},{"key":"null","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0960-9776(03)80158-3","volume":"12","author":"Mouridsen HT","year":"2003","unstructured":"Mouridsen HT, Rose C, Brodie AH, Smith IE. Challenges in the endocrine management of breast cancer. Breast, 2003, 12: S2-S19.","journal-title":"Breast"},{"key":"null","first-page":"1643","volume":"3","author":"Newby JC","year":"1997","unstructured":"Newby JC, Johnston S, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res, 1997, 3: 1643-1651.","journal-title":"Clin Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","volume":"96","author":"Shou J","year":"2004","unstructured":"Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2\u2013positive breast cancer. J Natl Cancer Inst, 2004, 96: 926-935.","journal-title":"J Natl Cancer Inst"},{"key":"null","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01961241","volume":"24","author":"Benz CC","year":"1992","unstructured":"Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu. Breast Cancer Res Treat, 1992, 24: 85-95.","journal-title":"Breast Cancer Res Treat"},{"key":"null","first-page":"2435","volume":"10","author":"Pietras RJ","year":"1995","unstructured":"Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 1995, 10: 2435-2446.","journal-title":"Oncogene"},{"key":"null","first-page":"3350","volume":"56","author":"Tang CK","year":"1996","unstructured":"Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R. Involvement of heregulin-\u03b22 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res, 1996, 56: 3350-3358.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1158\/1078-0432.CCR-05-0196","volume":"11","author":"Tovey S","year":"2005","unstructured":"Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer. Clin Cancer Res, 2005, 11: 4835-4842.","journal-title":"Clin Cancer Res"},{"key":"null","first-page":"707","volume":"1","author":"Clark AS","year":"2002","unstructured":"Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther, 2002, 1: 707-717.","journal-title":"Mol Cancer Ther"},{"key":"null","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","volume":"10","author":"Friedrichs WE","year":"2004","unstructured":"Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res, 2004, 10: 8059-8067.","journal-title":"Clin Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/B:BREA.0000041623.21338.47","volume":"87","author":"Jordan NJ","year":"2004","unstructured":"Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI. Increased constitutive activity of PKB\/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat, 2004, 87: 167-180.","journal-title":"Breast Cancer Res Treat"},{"key":"null","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2010.34.3996","volume":"29","author":"Seruga B","year":"2011","unstructured":"Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol, 2011, 29: 3686-3694.","journal-title":"J Clin Oncol"},{"key":"null","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.yexcr.2010.01.009","volume":"316","author":"Kruser TJ","year":"2010","unstructured":"Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res, 2010, 316: 1083-1100.","journal-title":"Exp Cell Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","volume":"3","author":"Yonesaka K","year":"2011","unstructured":"Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med, 2011, 3:","journal-title":"Sci Transl Med"},{"key":"null","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1756-8722-6-38","volume":"6","author":"Incorvati JA","year":"2013","unstructured":"Incorvati JA, Shah S, Mu Y, Lu J. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol, 2013, 6:","journal-title":"J Hematol Oncol"},{"key":"null","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2012.09.008","volume":"22","author":"Nielsen DL","year":"2013","unstructured":"Nielsen DL, Kumler I, Palshof JA, Andersson M. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast, 2013, 22: 1-12.","journal-title":"Breast"},{"key":"null","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ctrv.2012.04.008","volume":"39","author":"Hurvitz SA","year":"2013","unstructured":"Hurvitz SA, Hu Y, O'Brien N, Finn RS. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev, 2013, 39: 219-229.","journal-title":"Cancer Treat Rev"},{"key":"null","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","volume":"17","author":"Rexer BN","year":"2012","unstructured":"Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog, 2012, 17: 1-16.","journal-title":"Crit Rev Oncog"},{"key":"null","doi-asserted-by":"crossref","first-page":"127rv122","DOI":"10.1126\/scitranslmed.3001539","volume":"4","author":"Stern HM","year":"2012","unstructured":"Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med, 2012, 4:","journal-title":"Sci Transl Med"},{"key":"null","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","volume":"12","author":"Berns K","year":"2007","unstructured":"Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell, 2007, 12: 395-402.","journal-title":"Cancer Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nm.2309","volume":"17","author":"Zhang S","year":"2011","unstructured":"Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med, 2011, 17: 461-469.","journal-title":"Nat Med"},{"key":"null","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1535-6108(02)00097-1","volume":"2","author":"Agus DB","year":"2002","unstructured":"Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell, 2002, 2: 127-137.","journal-title":"Cancer Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","volume":"93","author":"Lu Y","year":"2001","unstructured":"Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J Natl Cancer Inst, 2001, 93: 1852-1857.","journal-title":"J Natl Cancer Inst"},{"key":"null","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","volume":"65","author":"Nahta R","year":"2005","unstructured":"Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res, 2005, 65: 11118-11128.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/0008-5472.CAN-09-3321","volume":"70","author":"Huang X","year":"2010","unstructured":"Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res, 2010, 70: 1204-1214.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"Geyer CE","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 2006, 355: 2733-2743.","journal-title":"N Engl J Med"},{"key":"null","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1158\/1078-0432.CCR-08-0581","volume":"14","author":"Chen FL","year":"2008","unstructured":"Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res, 2008, 14: 6730-6734.","journal-title":"Clin Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12325-009-0012-y","volume":"26","author":"McArthur H","year":"2009","unstructured":"McArthur H. An overview of HER-targeted therapy with lapatinib in breast cancer. Adv Ther, 2009, 26: 263-271.","journal-title":"Adv Ther"},{"key":"null","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","volume":"68","author":"Eichhorn PJ","year":"2008","unstructured":"Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res, 2008, 68: 9221-9230.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1038\/onc.2011.130","volume":"30","author":"Rexer BN","year":"2011","unstructured":"Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, Gonzalez-Angulo AM, Mills GB. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene, 2011, 30: 4163-4174.","journal-title":"Oncogene"},{"key":"null","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/0008-5472.CAN-12-1803","volume":"73","author":"Zhang S","year":"2013","unstructured":"Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res, 2013, 73: 5764-5774.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1172\/JCI65780","volume":"123","author":"Abel EV","year":"2013","unstructured":"Abel EV, Basile KJ, Kugel CH, Witkiewicz AK, Le K, Amaravadi RK, Karakousis GC. Melanoma adapts to RAF\/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest, 2013, 123: 2155-2168.","journal-title":"J Clin Invest"},{"key":"null","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","volume":"3","author":"Montero-Conde C","year":"2013","unstructured":"Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov, 2013, 3: 520-533.","journal-title":"Cancer Discov"},{"key":"null","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-8722-4-18","volume":"4","author":"Sartor AO","year":"2011","unstructured":"Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol, 2011, 4:","journal-title":"J Hematol Oncol"},{"key":"null","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.molonc.2012.07.001","volume":"6","author":"Bezler M","year":"2012","unstructured":"Bezler M, Hengstler JG, Ullrich A. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol, 2012, 6: 516-529.","journal-title":"Mol Oncol"},{"key":"null","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1038\/onc.2010.180","volume":"29","author":"Wang S","year":"2010","unstructured":"Wang S, Huang X, Lee CK, Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of survivin. Oncogene, 2010, 29: 4225-4236.","journal-title":"Oncogene"},{"key":"null","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11912-012-0215-2","volume":"14","author":"Church DN","year":"2012","unstructured":"Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep, 2012, 14: 120-128.","journal-title":"Curr Oncol Rep"},{"key":"null","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.drudis.2011.04.001","volume":"16","author":"Kanwar JR","year":"2011","unstructured":"Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today, 2011, 16: 485-494.","journal-title":"Drug Discov Today"},{"key":"null","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1476-4598-10-35","volume":"10","author":"Kelly RJ","year":"2011","unstructured":"Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer, 2011, 10:","journal-title":"Mol Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","volume":"17","author":"Katso R","year":"2001","unstructured":"Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol, 2001, 17: 615-675.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1023781114568","volume":"22","author":"Reddy KB","year":"2003","unstructured":"Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev, 2003, 22: 395-403.","journal-title":"Cancer Metastasis Rev"},{"key":"null","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","volume":"22","author":"Summy JM","year":"2003","unstructured":"Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev, 2003, 22: 337-358.","journal-title":"Cancer Metastasis Rev"},{"key":"null","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ncb1094","volume":"6","author":"Webb DJ","year":"2004","unstructured":"Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol, 2004, 6: 154-161.","journal-title":"Nat Cell Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-05-0550","volume":"66","author":"Xue C","year":"2006","unstructured":"Xue C, Liang F, Mahmood R, Vuolo M, Wyckoff J, Qian H, Tsai KL. ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res, 2006, 66: 1418-1426.","journal-title":"Cancer Res"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/521D76A23CF54B119FEC3CF2596EC7A6","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmt150","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/521D76A23CF54B119FEC3CF2596EC7A6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:32:44Z","timestamp":1746117164000},"score":1,"resource":{"primary":{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmt150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":114,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,1]]},"published-print":{"date-parts":[[2014,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abbs\/gmt150","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3,1]]}}}